Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Clinical trial NCT05352672 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05352672
- Sponsor
- Regeneron Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-14
- Primary completion
- 2026-03-12
- Enrollment
- 1546
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.